Purchase Order 36C26122P0579
Award Date
2/11/22
Potential Completion Date
9/30/22
Potential Value
$125K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Accredo Health Group, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Palo Alto, CA 94304, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract, valued at $160,429.83, is for the delivery of the medication Uptravi 1600mcg, which is used to treat pulmonary arterial hypertension (PAH). The contract is part of the VA's efforts to provide critical medications to veterans through its Veterans...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit specialty pharmacy company. The contract is for a 180-day supply of the medication Uptravi 600mcg, with a ceiling value of $78,557.34. The contract is not designated as a set-aside. Accredo Health Group, Inc. is a key distributor of complex and high-value medications to the VA's Veterans Integrated Service Networks (VISNs), with a focus on drugs...
Accredo Health Group, Inc. was awarded a firm fixed price purchase order without set-aside by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The order is for the delivery of TYVASO to the Palo Alto, California location, with a potential value of $47,594.01 and completion by May 22, 2023. As a prime contractor supporting the VA through its national pharmaceutical contracts, Accredo Health Group will distribute this specialized pulmonary...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the delivery of UPTRAVI 1600MCG, a medication used to treat pulmonary arterial hypertension, under a larger VA contract vehicle (36F79719D0142). The contract has a ceiling value of $166,022.23 and a performance period ending on January 11, 2025. Accredo Health Group, Inc. is a subsidiary of...
The Department of Veterans Affairs Veterans Health Administration awarded a $13,557 purchase order to Accredo Health Group, Inc. to deliver TYVASO in Palo Alto, California from January 18, 2023 through April 18, 2023. As a prime contractor supporting VA's Veterans Integrated Service Network 21, Accredo Health Group will provide the pulmonary arterial hypertension medication on a firm fixed price basis. No subcontractors or set aside designations were indicated. This purchase order was issued...
This is a $40,697.68 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the supply of specialty pharmaceutical products, including medications to treat pulmonary arterial hypertension, neuropathic lysosomal storage disorders, and ophthalmic disorders. The contract has an ultimate completion date of March 14, 2025 and is part of the VA's Veterans...
The U.S. Department of Veterans Affairs (VA) awarded a $81,342.18 firm fixed-price purchase order contract to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical TYVASO. The contract, which does not have a set-aside designation, is to support the VA's Veterans Integrated Service Network 21 (VISN 21) and has an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and...
The U.S. Department of Veterans Affairs (VA) awarded a $43,162 firm fixed-price purchase order to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical Prolastin. This contract is not associated with a set-aside program and has an ultimate completion date of June 30, 2024. Accredo Health Group, Inc., a subsidiary of Express Scripts, is a key distributor of complex and high-value medications, primarily serving the healthcare needs of...
This is a $103,003.20 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company specializing in specialty pharmaceutical services. The contract is for the delivery of various complex and high-value medications, primarily to support the VA's Veterans Integrated Service Network (VISN) healthcare facilities. Key medications provided under this contract include drugs used to treat...
This is a $81,632.25 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit subsidiary of Express Scripts that specializes in providing specialty pharmaceutical services. The contract is for the delivery of the medication Tyvaso, which is used to treat pulmonary arterial hypertension. The contract has no set-aside designation and was awarded on April 6, 2021, with a completion date of September 30, 2021....